Pharnext (FR:ALPHA) has released an update.
Pharnext, a clinical-stage biopharmaceutical company, has disclosed its total number of shares and voting rights, alongside a warning about potential share value decrease and dilution from financing operations involving Global Tech Opportunities 13 and a trust. The company is developing PXT3003, a drug candidate for Charcot-Marie-Tooth disease, which has orphan drug status in Europe and the US.
For further insights into FR:ALPHA stock, check out TipRanks’ Stock Analysis page.